Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 7/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | JUN | P05412 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700990 | 0.82 | FLT3 (0.52) | FLT3PKMCDK2IGF1RDYRK1A | |
| SCHEMBL3314551 | 0.82 | FLT3 (0.48) | FLT3PKMCDK2IGF1RDYRK1A | |
| SCHEMBL3313332 | 0.80 | FLT3 (0.46) | FLT3PKMCDK2IGF1RDYRK1A | |
| SCHEMBL3315346 | 0.80 | DYRK1A (0.46) | FLT3PKMCDK2IGF1RDYRK1A | |
| SCHEMBL3313051 | 0.76 | PIK3CA (0.53) | FLT3PKMCDK2IGF1RDYRK1A | |
| SCHEMBL2196334 | 0.74 | IDO1 (0.36) | — | |
| SCHEMBL182990 | 0.71 | DYRK1A (0.66) | FLT3PKMCDK2IGF1RDYRK1A | |
| SCHEMBL28211031 | 0.70 | KMT2A (0.43) | DYRK1A | |
| SCHEMBL17373080 | 0.69 | KDM4E (0.41) | CDK2IGF1RDYRK1APLK1JUN | |
| SCHEMBL15757217 | 0.69 | FLT3 (0.69) | FLT3PKMCDK2DYRK1AMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | FLT3 191/4885PKM 960/4885CDK2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.